Key result
Full adherence to statins and ACE inhibitors linked to ~27% lower major cardiovascular events risk post-MI.
Why the study?
Guideline-recommended therapies reduce MACE in patients after MI or with atherosclerotic disease, but adherence is poor, prompting evaluation of the association between adherence levels and long-term MACE.
Does full adherence to statins and ACE inhibitors reduce the composite of death, MI, stroke, or coronary revascularization in patients post-MI or with atherosclerotic disease?
Cohort (n=16,991)
Does full adherence to statins and ACE inhibitors reduce the composite of death, MI, stroke, or coronary revascularization in patients post-MI or with atherosclerotic disease?
Full adherence to statins and ACE inhibitors is associated with significantly lower rates of major adverse cardiovascular events and reduced medical costs in patients post-MI or with atherosclerotic disease.
Answers are grounded in this paper and cite their sources.
Supports adherence monitoring in secondary prevention; extends observational data but leaves causal effects open for trials.
BACKGROUND: Although guideline-recommended therapies reduce major adverse cardiovascular events (MACE) in patients after myocardial infarction (MI) or those with atherosclerotic disease (ATH), adherence is poor. OBJECTIVES: The goal of this study was to determine the association between medication adherence levels and long-term MACE in these patients. METHODS: We queried the claims database of a large health insurer for patients hospitalized for MI or with ATH. The primary outcome measure was a composite of all-cause death, MI, stroke, or coronary revascularization. Using proportion of days covered for statins and angiotensin-converting enzyme inhibitors, patients were stratified as fully adherent (≥80%), partially adherent (≥40% to ≤79%), or nonadherent (<40%). Per-patient annual direct medical (ADM) costs were estimated by using unit costs from 2 national files. RESULTS: Data were analyzed for 4,015 post-MI patients and 12,976 patients with ATH. In the post-MI cohort, the fully adherent group had a significantly lower rate of MACE than the nonadherent (18.9% vs. 26.3%; hazard ratio [HR]: 0.73; p = 0.0004) and partially adherent (18.9% vs. 24.7%; HR: 0.81; p = 0.02) groups at 2 years. The fully adherent group had reduced per-patient ADM costs for MI hospitalizations of $369 and $440 compared with the partially adherent and nonadherent groups, respectively. In the ATH cohort, the fully adherent group had a significantly lower rate of MACE than the nonadherent (8.42% vs. 17.17%; HR: 0.56; p < 0.0001) and the partially adherent (8.42% vs. 12.18%; HR: 0.76; p < 0.0001) groups at 2 years. The fully adherent group had reduced per-patient ADM costs for MI hospitalizations of $371 and $907 compared with the partially adherent and nonadherent groups. CONCLUSIONS: Full adherence to guideline-recommended therapies was associated with a lower rate of MACE and cost savings, with a threshold effect at >80% adherence in the post-MI population; at least a 40% level of long-term adherence needs to be maintained to continue to accrue benefit. Novel approaches to improve adherence may significantly reduce cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Bansilal et al. (2016) conducted a cohort in Myocardial infarction or atherosclerotic disease (n=16,991). Full medication adherence (≥80%) to statins and ACE inhibitors vs. Nonadherence (<40%) was evaluated on Composite of all-cause death, MI, stroke, or coronary revascularization (HR 0.73, p=0.0004). Full adherence to statins and ACE inhibitors was associated with a lower rate of major cardiovascular events compared to nonadherence in post-MI and atherosclerotic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: